Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00347646 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00347646 is a Phase 1 study that was terminated before completion, run by Bausch & Lomb Incorporated. The registered enrollment target is 4 participants.
The verdict
NCT00347646, a Phase 1 study, was terminated before completion, sponsored by Bausch & Lomb Incorporated.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.
Interventions
- DRUG Plasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00347646
The ClinicalTrials.gov registry entry for NCT00347646 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plasmin is the first listed.
NCT00347646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00347646 about?
NCT00347646 is a clinical study titled "A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)". Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.
What is the current status of trial NCT00347646?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2006-09. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00347646?
The interventions under investigation include: Plasmin (DRUG).
Who is sponsoring clinical trial NCT00347646?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.